InvestSMART

Polynovo Limited (ASX:PNV)

ALERT: Price-sensitive ASX Announcement for PNV
Current share price for PNV : $0.870 -0.335 (-27.80%)+
Announcement
Release
19 Jan 2026 8:32AM
Price at Release
$1.205
Full Release
download
Summary
PolyNovo Limited announced its unaudited trading results for the first half of the financial year 2026, reporting a 26.0% increase in group sales totaling A$68.2 million. This growth was driven by significant sales increases in major markets including the U.S., where sales rose to A$51.7 million, and notable performances in Australia, Canada, Germany, Ireland, and Turkey. However, revenue from BARDA decreased by 62.5% due to the completion of a pivotal trial. The company reported a positive cash flow from operations amounting to A$9.5 million, marking a substantial turnaround from the previous year. The completion of a new manufacturing facility and ongoing strategic initiatives, such as submission for Medicare coverage for NovoSorb products, are positioned to support future growth. The company highlighted the strong adoption of its NovoSorb MTX product, which significantly contributed to the revenue increase. The leadership under the newly appointed CEO, Bruce Peatey, is focused on sustaining growth momentum, expanding product lines, and enhancing customer support.
Key Points
  • Group sales increased by 26.0% to A$68.2 million.
  • U.S. sales rose by 25.3% to A$51.7 million.
  • NovoSorb MTX sales increased by 195.2%.
  • Total group revenue including BARDA was A$70.4 million.
  • Cash flow from operations was A$9.5 million, a positive shift from the previous year.
  • New manufacturing facility completed with A$2.2 million capex outstanding.
  • Pre-market approval submission for U.S. full thickness burns trial is on track.
  • CMS submission for Medicare coverage of NovoSorb BTM is pending.
  • PolyNovo is focused on sustaining growth and expanding product offerings.
  • The CEO emphasized strong market growth and strategic initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.